Truvada is one of the few drugs identified to be capable of prolonging the life of HIV/AIDS patients
Scientists worldwide will gather in Boston next week to present more than 400 new research studies updating global progress in the search for a safe and effective HIV vaccine.
AIDS Vaccine 2012, the world's only and largest scientific meeting dedicated exclusively to HIV vaccine research, runs from September 9-12 at the Boston Convention and Exhibition Center.
The annual AIDS vaccine meeting is hosted by the Global HIV Vaccine Enterprise, a unique collaboration of HIV vaccine research, funding, advocacy and stakeholder organizations.
Local hosts are the Harvard University Center for AIDS Research and the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University.
"HIV vaccine research is in its most promising era since the epidemic began," said Bill Snow, Director of the Global HIV Vaccine Enterprise.
"With sound and well-financed implementation, new HIV prevention strategies could produce important reductions in the 2.5 million HIV infections occurring each year. At the same time, the development of a safe and effective AIDS vaccine remains central to efforts to bring us significantly closer to the end of this epidemic."
A new array of hope
A landmark 2009 HIV vaccine study known as RV144 in Thailand demonstrated the first proof of concept that an AIDS vaccine can prevent infection.
AIDS Vaccine 2012 will follow up with new research exploring potential mechanisms on how and why that vaccine candidate may have worked, present new data on the workings of the human immune system that can help steer future vaccine design; and share updates on new neutralizing antibodies that protect against a wide range of HIV strains, which are driving new technologies.
Under the theme New Minds, New Ideas, New Approaches, AIDS Vaccine 2012 will host, for the first time, sessions exploring synergies between the most promising areas of HIV biomedical prevention research including HIV cure, microbicides and treatment as prevention and HIV vaccine research.
The conference program also includes other, potentially more powerful emerging immunological approaches to enhance HIV vaccine delivery and development.
Boston is at the forefront of global technological innovation and is home to scientific collaborations that are accelerating HIV biomedical prevention research. AIDS Vaccine 2012 is the result of collaborations between the Ragon Institute and three independent Centers for AIDS Research (CFARs) in New England.
Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center and chair of AIDS Vaccine 2012Dan Barouch, M.D., Ph.D says “recent progress has also inspired new ideas and new approaches to the design and testing of next generation HIV vaccine candidates.
We are pleased to welcome researchers from around the world to AIDS Vaccine 2012 to share their recent discoveries and to engage in these important discussions."
The AIDS Vaccine 2012 will also showcase the work of young and early-career investigators, the generation of researchers who are emerging to carry HIV vaccine research and development forward faster.
More than 45 percent of the conference program includes presentations on the latest cutting-edge research by early-career investigators.
“Past approaches to vaccine design and testing have not yet yielded a safe and effective vaccine that the world so urgently needs.
New ideas and novel perspectives are therefore eminently needed to achieve an HIV vaccine as soon as possible," said Galit Alter, an Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital and chair of AIDS Vaccine 2012.
"At AIDS Vaccine 2012, we will hear how scientists, many who are new to the field, are using novel technologies and out-of-the-box approaches to take HIV vaccine research to the next phase of discovery to help end this epidemic", says Galit Alter.